Umm Al-Qura University
Umm Al-Qura University
About
Overview
The University's Organizational Structure
University Geographical Sites
Administration
President of the University
Vice-deans
Deanships
Departments
Colleges
Medicine colleges
College of Medicine
College of Applied Medical Sciences
College of Dentistry
College of Public Health and Health Informatics
College of Pharmacy
College of Nursing
Science and engineering colleges
College of Sciences
College of Engineering and Architecture
College of Computers
Shari'ah and administration colleges
College of Shari’ah and Islamic Studies
College of Da'wa and Islamic Theology
College of Administration and Economy
College of Judicial Studies and Regulations
Colleges of Humanities and Educational Sciences
College of Arabic Language
College of Education
College of Social Sciences
Arabic Language for Non-native Speakers
Makkah Community College
College of Designs and Arts
English Language Center
Branch colleges
Qunfudah Campus
Al-Leith Campus
Jamoum Campus
Adham Campus
Research & Innovation
King Abdullah University Library
Research institutes
Scientific journals
Research Chairs Program
Electronic Services
Administrative services
E-Tickets
e-Workflows
Reservations and Appoints
General services
E-Services Index
Recruitment gate
Who Messaged Me ?
Contact center
University Geographical Sites
Transaction Inquiry
UQU Email Activation
Graduation document verification
Medical Center Clinic Appointments
The Electronic Maqraah of Umm Al-Qura University
Open Data Platform
Back to UQU Homepage
CVs
Contact
Hala Fouad Jameel Azhari
Search in the Site
University Community
Login
University Email
Staff Email
Students Email
English
العربية
Search in the Site
University Community
University Email
Staff Email
Students Email
English
العربية
Search in the Site
×
Login
User Name
Password
Remember me
Forgot your Login details?
Check Email Title
Single Login Explanation
Login to the National Single Sign-On (Absher)
×
Hala Fouad Jameel Azhari
Pharmacology
CVs
Contact
Homepage
Hala Fouad Jameel Azhari
e-Forms
Pharmacogenomics test use in stroke from the perspective of Saudi healthcare professionals: The PharmGxSurvey
From :
-
2022/05/07 م
, To :
-
2025/05/29 م
Participant’s invitation letter
This is an invitation to complete a survey that aims to understand the healthcare providers views about analysing the barriers preventing pharmacogenomic (PGx) test use in patients with stroke or at risk for stroke and primary and secondary stroke care services. This research study is being conducted by a team of researchers at Umm A-Qura University. We feel that this is an important study and hope that you are interested in participating in this research. However, we have not passed on your personal details, and you do not have to take part. To find out more about taking part in the questionnaire, please read the information sheet or contact the research team Via
;
https://uqu.edu.sa/hfazhari/App/Contact
.
The survey will take approximately 3-5 minutes to complete.
Participant’s invitation letter
This is an invitation to complete a survey that aims to understand the healthcare providers views about analysing the barriers preventing pharmacogenomic (PGx) test use in patients with stroke or at risk for stroke and primary and secondary stroke care services. This research study is being conducted by a team of researchers at Umm A-Qura University. We feel that this is an important study and hope that you are interested in participating in this research. However, we have not passed on your personal details, and you do not have to take part. To find out more about taking part in the questionnaire, please read the information sheet or contact the research team Via
;
https://uqu.edu.sa/hfazhari/App/Contact
.
The survey will take approximately 3-5 minutes to complete.
Study ethics
Step 1 From 4
*
Have you read the information sheet for this study (Pharmacogenomics test use in stroke. Exploring healthcare professionals’ views)
Yes
No
*
. If yes, do you agree to take part in the survey and for us to use your anonymous answers?
Yes
No
*
. Please confirm that this questionnaire is being completed by the person to whom it was sent.
Yes
No
Demographics Data
Step 1 From 4
*
What is your sex?
Female
Male
*
What is your age?
18-29
30-39
40-49
50-59
60-69
70-79
≥80 years
*
What is your level degree of education?
Diploma
Bachelor
Doctor of Philosophy (Ph.D.)
Master
Fellowship
Resident
Specialist
Consultant
Other
If you choose Other: (please specify)
*
What is your occupation?
Technician
Nurse
Pharmacist
Physician
Researcher
Other
If you choose Other: (please specify)
*
What is your medical specialty?
Anesthetics
Biochemistry
Cardiology
Clinical pharmacology
Emergency or acute medicine
Endocrinology
Family medicine
Gastroenterology
General pharmacy
Genetics
Infectious diseases
Hematology
Microbiology
Nephrology
Neurology
Obstetrics and genecology
Oncology
Pathology
Pediatrics
Primary care
Psychiatry
Radiology
Respiratory
Rheumatology
Surgery
Other
If you choose Other: (please specify)
*
Where is your primary hospital setting?
Samir Abbas hospital
Al-Zaher Hospital
King Abdullah Medical City
National Gard Hospital
King Faisal Specialist hospital
King Fahad hospital
Al-Noor Specialist hospital
King Fahad Armed Forces hospital
King Faisal hospital in Macca
Other (please specify)
If you choose Other: (please specify)
*
What is your primary practice setting?
Hospital outpatients or ambulatory care
Hospital inpatients
Community‐based nursing home
Academia
Research
Other
If you choose Other: (please specify)
*
What is your number of work experience?
1 year
2 to 5 years
6 to 10 years
11 to 15 years
16 to 20 years
Above 20 years
Pharmacogenomic (PGx) test knowledge
Step 1 From 4
*
Do you know the pharmacogenomics (PGx) test?
Yes
No
*
After reading the information about the benefit of PGx test, do you think performing a PGx test can determine the optimal drug selection for patients?
Strongly agree
Agree
Disagree
Strongly disagree
*
Do you think performing a PGx test can determine the correct doses for patients?
Strongly agree
Agree
Disagree
Strongly disagree
*
Do you think performing a PGx test can decrease the number of drugs prescription for patients?
Strongly agree
Agree
Disagree
Strongly disagree
*
Do you think performing a PGx test can decrease the duration of drugs prescription for patients?
Strongly agree
Agree
Disagree
Strongly disagree
*
Do you think performing a PGx test assist in preventing adverse drug reactions for patients?
Strongly agree
Agree
Disagree
Strongly disagree
*
In your opinion, can PGx DNA detection save medical costs and lower the economic burdens for patients?
Strongly agree
Agree
Disagree
Strongly disagree
*
In your opinion, which of following factors could hinder the clinical application of PGx test in Sausi Arabia? (Please select all that apply)
Not knowing PGx test
The cost of PGx test
Lacking a pricing standard for PGx DNA detection
Lacking large-scaled clinical trials of PGx
Lacking an application guideline of PGx
Lacking a reporting standardization for PGx DNA detection
Lacking sector codes of PGx’s clinical application
Not including PGx DNA detection into Medical Insurance Scheme
Other
If you choose Other: (please specify)
*
In your opinion, which of the following can help in understanding PGx test, and be easier to apply to a specific drug?
Genetic testing laboratory
Drug labels (package insert)
PharmGKB website
Youtube
Journal
Other
If you choose Other: (please specify)
Experience and attitude
Step 1 From 4
*
In your opinion, how important should the doctors know about PGx test?
Very important
Important
Slightly important
Not important
*
In your opinion, which of the following can be dependent in determining drug doses?
Indication
Age
Sex
Body mass index
Renal function
Liver function
Therapeutic drug monitoring
Pharmacogenomics (PGx)
Biomarker
Co-morbidities
Co-medication
Other
If you choose Other: (please specify)
*
In your opinion, which of the following may be a reason to request a PGx test?
Obligatory companion diagnostic
Preventing/explaining side effects
Drug dose adjustments
For research purposes
Tumor diagnostic
Other
If you choose Other: (please specify)
*
In your opinion, which of the following may be a reason to refuse request a PGx test?
Concerns about privacy
Uncertain, or little about the value of PGx testing
Lack of insurance coverage for PGx testing
Not enough personal knowledge about PGx testing
Not familiar with the legal issues and regulations of PGx testing
Patients’ refuse of PGx testing
I do not prescribe drugs with PGx tests available or recommended
Other
If you choose Other: (please specify)
*
When treated patients with stroke or at risk for stroke, in your opinion which of the following drugs are associated with PGx assays? (Please select all that apply)
Anticoagulant drugs such as warfarin and/or rivaroxaban
Antiplatelets drugs such as aspirin, clopidogrel, ticagrelor and/or prasugrel
Antihypertensive drugs such as ꞵ-blocker as metoprolol, nebivolol and/or propranolol
Antihyperlipidemic drugs such as statins
Not knowing a stroke drugs with a PGx assays
*
In your opinion, which of the following would you prefer to learn PGx in the future? (Please select all that apply)
Formulate the relevant clinical guidelines of individualized PGx therapy in SA
Implemented PGx-guided dosing protocols and PGx assays in clinical practice in SA
Establish a PGx knowledge database in SA
Scientific article
Conference talk
Accredited learning course and workshop
Continuing medical education
Patient cases
Medical app
E‐learning course
Other
If you choose Other: (please specify)
Previous
Next
Loading
×
close